STOCKS TELEGRAPH

Tag: Aditxt Stock

  • Aditxt (ADTX) Stock Rises Sharply In Pre-Market As Investors React To New Strategy

    Aditxt (ADTX) Stock Rises Sharply In Pre-Market As Investors React To New Strategy

    Aditxt, Inc. (NASDAQ: ADTX) saw a sharp rise in its stock value after announcing key strategic initiatives. As of the latest pre-market check, ADTX shares were trading at $6.12, up 40.05%, reflecting strong investor confidence.

    Advancements in Clinical Trials and Regulatory Efforts

    Aditxt provided a corporate update highlighting progress across its subsidiaries. Adimune Inc. is advancing toward clinical trials, having shipped drug substances for ADI-100. It is preparing an Investigational New Drug (IND) application for Stiff Person Syndrome (SPS) in partnership with the Mayo Clinic and a Clinical Trial Application for Type 1 Diabetes (T1D) and Psoriasis in Germany. Clinical trials for these conditions are planned in both Germany and the U.S.

    Pearsanta Prepares for IPO and Commercial Launch

    Pearsanta, Inc., Aditxt’s precision diagnostics subsidiary, is set for a commercial launch in late 2025, starting with blood-based tests for Prostate Cancer and Endometriosis. The company has engaged Dominari Securities LLC as the lead underwriter for its planned IPO, aiming to fund commercialization and expand its Mitomic Technology platform for early cancer detection. A randomized controlled study for the Mitomic Prostate Test is also in progress.

    Adivue Focuses on Neurological Monitoring

    Following its acquisition of Brain Scientific assets, Aditxt is launching commercialization efforts through its subsidiary, Adivue, Inc. Adivue is working toward FDA re-approval of Brain Scientific’s electroencephalogram (EEG) device and establishing strategic partnerships for product development and commercial launch.

    Strategic Partnerships and Business Expansion

    Aditxt has extended its agreement with Appili Therapeutics, Inc. through March 2025, completing the required $250,000 payments. The company is also evaluating additional opportunities with Appili. Similarly, ADTXand Evofem Biosciences, Inc. continue discussions on integrating Evofem into Aditxt’s business acceleration platform.

    Commitment to Transparency with Weekly Updates

    To enhance communication, the company is launching the Aditxt Weekly Update series on March 21, 2025. The first session will feature a discussion between CEO Amro Albanna and Saundra Pelletier, offering insights into corporate strategy and future plans.

    ADTX remains focused on advancing subsidiaries toward key milestones while executing its acquisition strategy, reinforcing its commitment to innovation and growth.

  • Decoding The Spike: Understanding Aditxt (ADTX) Shares’ Significant Increase

    Decoding The Spike: Understanding Aditxt (ADTX) Shares’ Significant Increase

    Aditxt, Inc. (NASDAQ: ADTX) is observing a notable surge of 25.47% in its shares during the current session, escalating to a price of $3.99. This significant increase in ADTX shares within the US market can be directly attributed to the disclosure of an acquisition agreement.

    Aditxt (ADTX) officially stated today that it has reached a formal arrangement agreement to acquire Appili Therapeutics Inc. is a biopharmaceutical company that emphasis on developing drugs for infectious illnesses and medical countermeasures.

    Adivir, Inc., Aditxt’s wholly owned subsidiary, has agreed to purchase all of Appili’s issued and outstanding Class A common shares under a court-approved plan of arrangement under the Canada Business Corporations Act.

    The FDA-approved LIKMEZ (formerly ATI-1501), the ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the US Department of Defense, and ATI-1801, a topical formulation aimed at cutaneous leishmaniasis—a crippling disease that causes pain and disfigurement—are just a few of the varied portfolio items that Appili has developed since its establishment in 2015.

    This acquisition will enrich Aditxt’s array of subsidiaries and foster synergies with its existing initiatives, notably in precision diagnostics. The amalgamation of Appili’s proficiency and product lines will facilitate a holistic approach to public health, encompassing early detection, prevention, and treatment. Collaborative opportunities within the Aditxt ecosystem promise to streamline patient care, from early detection through precise diagnostics to tailored treatment strategies.

    The incorporation of Appili into Aditxt’s framework signifies another stride in advancing promising health innovations. With the integration of Appili’s proven track record and broad portfolio in biodefense and infectious illnesses, Aditxt is well-positioned to have a substantial impact on the development of public health solutions.

    Under the Canada Business Corporations Act, the Transaction will take place through a plan of arrangement that has been approved by the court. Adivir will purchase all issued and outstanding Appili Shares in accordance with the provisions of the Arrangement Agreement, and each Appili Shareholder will receive US$0.0467 for each Appili Share held in addition to 0.002745004 of a share of Aditxt’s common stock.

    The Transaction is contingent upon the approval of at least two-thirds of the votes cast at the special meeting of the Appili Shareholders, projected to convene before the conclusion of calendar Q2 2024 for approval of the Transaction.

  • On What Basis Did ADTX Stock Rise In Premarket Trading?

    As of Tuesday’s last check, Aditxt Inc. (ADTX) was up 20.43% at $2.83 in pre-market trading hours. ADTX closed the last trading session unchanged at $2.35. Shares of ADTX traded between $2.27 and $2.55. ADTX traded 0.71 million shares, which was higher than its daily average of 0.27 million shares over 100 days. ADTX stock gained 2.17% in the last five days, while they lost -10.31% last month. Recent developments may provide more insight into ADTX stock as it has risen without current news.

    ADTX has anything new happened recently?

    Aditxt develops technologies specifically focused on the improvement of immune health through immune monitoring and reprogramming. In the ADTX immune monitoring technology, a comprehensive immune profile is provided to each patient on a personal basis. ADTX’s immune reprogramming technology is currently at the preclinical stage and targets transplant rejection, autoimmune diseases, and allergies by retraining the immune system to induce tolerance.

    Aditxt announced a new and improved version of its AditxtScore for COVID-19.

    • AditxtScore for COVID-19 is a multidimensional immune response test that monitors several combinations of the immune system’s reactions to certain antigens at the same time.
    • ADTX also enhanced its AditxtScore for COVID-19 to include a SARS-CoV-2 virus neutralizing antibody test, allowing it to assess an individual’s immune response.
    • AditxtScore for COVID-19 was released in August of 2020.
    • By comparing multiple antigens associated with the SARS-CoV-2 virus, it provides a detailed picture of an individual’s immune response.
    • The multi-multiplex screening tool developed by ADTX gives an individual a comprehensive picture of their immune response based on an expanded set of biomarkers associated with SARS-CoV-2.
    • AditxtScore for COVID-19 now includes the ability to measure neutralizing antibodies, which are virus-specific antibodies that prevent infection by preventing viral particles from entering cells.
    • As a result of AditxtScore’s precision and ability to measure individual’s reaction to COVID-19, clinicians can better understand a patient’s immune response to COVID-19, whether incurred through exposure, infection or vaccination.
    • This tool can also identify individuals who are susceptible to SARS-CoV-2 infection for a variety of reasons, such as their inability to respond adequately to vaccination or infection, as well as their lack of prior exposure to the virus.

    How ADTX Stock will be leveraging AditxtScore?

    Based on ADTX’s research on individual immune responses to COVID-19 and COVID-19 vaccinations, ADTX found that the intensity, duration, and timing of antibody responses can vary widely. AditxtScore with neutralizing antibody diagnostics for COVID-19 enables ADTX to provide more detailed information about how well a person’s immune system responds to the virus as more people become vaccinated or exposed to the virus.